Nebivolol Krka

Nebivolol, the active ingredient in Nebivolol Krka, is a β1‑selective beta‑blocker presented as an oral tablet for oral administration. It is used to lower blood pressure in essential hypertension and to improve cardiac function in adults with heart failure and reduced ejection fraction.

GNH USA supplies Nebivolol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Nebivolol is indicated for cardiovascular conditions that involve elevated blood pressure or impaired cardiac output.

- Essential hypertension: reduces systolic and diastolic blood pressure, helping achieve target levels. - Heart failure with reduced ejection fraction: improves ventricular function and decreases hospitalization risk. - Left ventricular systolic dysfunction: enhances ejection fraction and overall cardiac performance.

Nebivolol may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects: - Fatigue - Headache - Dizziness - Bradycardia - Nausea - Peripheral edema

Serious or Rare Side Effects: - Bronchospasm - Severe bradycardia or heart block - Marked hypotension - Allergic reactions (rash, angioedema) - Hepatic dysfunction - Exacerbation of heart failure

Before prescribing Nebivolol, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate heart rate and blood pressure prior to initiation. - Respiratory conditions: use cautiously in patients with asthma or COPD. - Diabetes management: monitor glucose as beta‑blockade may mask hypoglycaemia symptoms. - Concomitant medications: review other antihypertensives to avoid excessive hypotension. - Renal impairment: adjust dose in severe renal dysfunction per clinical judgment. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Nebivolol can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Combined use with other β‑blockers may cause profound bradycardia. - Calcium‑channel blockers verapamil or diltiazem can precipitate AV‑block. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine) increase nebivolol plasma levels. - Insulin or sulfonylureas may have hypoglycaemia‑masking effects. - Abrupt discontinuation of clonidine while on nebivolol can lead to rebound hypertension.

Moderate Interactions (Monitor Closely): - NSAIDs may attenuate antihypertensive efficacy. - Diuretics can heighten electrolyte disturbances. - ACE inhibitors may enhance hypotensive response. - Digoxin may increase risk of bradycardia. - Other antidepressants may require dose adjustments or monitoring.